0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Nonalcoholic Steatohepatitis (NASH) - Market Insight, Epidemiology and Market Forecast – 2028
Published Date: April 2019
|
Report Code: DELV-Mark-135
Home | Market Reports | Health
Nonalcoholic Steatohepatitis Market Insight Epidemiology and Market Forecast 2028

Nonalcoholic Steatohepatitis (NASH) - Market Insight, Epidemiology and Market Forecast – 2028

Code: DELV-Mark-135
Report
April 2019
100 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Nonalcoholic Steatohepatitis (NASH) - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Nonalcoholic Steatohepatitis (NASH) epidemiology and market outlook for the 7MM.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Nonalcoholic Steatohepatitis (NASH) Understanding and Treatment Algorithm
The market report provides the overview of the Nonalcoholic Steatohepatitis (NASH) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Nonalcoholic Steatohepatitis (NASH) Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Nonalcoholic Steatohepatitis (NASH) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Nonalcoholic Steatohepatitis (NASH) Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Nonalcoholic Steatohepatitis (NASH) Market Outlook
The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Nonalcoholic Steatohepatitis (NASH) market.

Nonalcoholic Steatohepatitis (NASH) Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Nonalcoholic Steatohepatitis (NASH) Report Insights
• Patient Population in Nonalcoholic Steatohepatitis (NASH)
• Therapeutic Approaches in Nonalcoholic Steatohepatitis (NASH)
• Nonalcoholic Steatohepatitis (NASH) Pipeline Analysis
• Nonalcoholic Steatohepatitis (NASH) Market Size and Trends
• Nonalcoholic Steatohepatitis (NASH) Market Opportunities
• Impact of upcoming Therapies in Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH) Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Nonalcoholic Steatohepatitis (NASH) Report Assessment
• Current Treatment Practices in Nonalcoholic Steatohepatitis (NASH)
• Unmet Needs in Nonalcoholic Steatohepatitis (NASH)
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• The report will help to develop Business Strategies by understanding the trends shaping and driving the Nonalcoholic Steatohepatitis (NASH) market
• Organize sales and marketing efforts by identifying the best opportunities for Nonalcoholic Steatohepatitis (NASH) market
• To understand the future market competition in the Nonalcoholic Steatohepatitis (NASH) market.

1. Report Introduction
2. Nonalcoholic Steatohepatitis (NASH) Market Overview at a Glance
2.1. Market Share Distribution of Nonalcoholic Steatohepatitis (NASH) in 2016
2.2. Market Share Distribution of Nonalcoholic Steatohepatitis (NASH) in 2028
3. Disease Background and Overview: Nonalcoholic Steatohepatitis (NASH)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Nonalcoholic Steatohepatitis (NASH) in 7MM
4.3. Total Prevalent Patient Population of Nonalcoholic Steatohepatitis (NASH) in 7MM – By Countries
5. Epidemiology of Nonalcoholic Steatohepatitis (NASH) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH)
5.1.3. Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) *
5.1.4. Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) *
5.1.5. Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH)
5.1.6. Treatable Cases of the Nonalcoholic Steatohepatitis (NASH)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH)
5.4.3. Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) *
5.4.4. Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) *
5.4.5. Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH)
5.4.6. Treatable Cases of the Nonalcoholic Steatohepatitis (NASH)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH)
5.5.3. Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) *
5.5.4. Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) *
5.5.5. Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH)
5.5.6. Treatable Cases of the Nonalcoholic Steatohepatitis (NASH)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH)
5.6.3. Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) *
5.6.4. Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) *
5.6.5. Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH)
5.6.6. Treatable Cases of the Nonalcoholic Steatohepatitis (NASH)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH)
5.7.3. Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) *
5.7.4. Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) *
5.7.5. Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH)
5.7.6. Treatable Cases of the Nonalcoholic Steatohepatitis (NASH)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH)
5.8.3. Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) *
5.8.4. Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) *
5.8.5. Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH)
5.8.6. Treatable Cases of the Nonalcoholic Steatohepatitis (NASH)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH)
5.9.3. Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) *
5.9.4. Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) *
5.9.5. Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH)
5.9.6. Treatable Cases of the Nonalcoholic Steatohepatitis (NASH)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Nonalcoholic Steatohepatitis (NASH)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Nonalcoholic Steatohepatitis (NASH)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Nonalcoholic Steatohepatitis (NASH) : 7MM Market Analysis
12.1. 7MM Market Size of Nonalcoholic Steatohepatitis (NASH)
12.2. 7MM Percentage Share of drugs marketed for Nonalcoholic Steatohepatitis (NASH)
12.3. 7MM Market Sales of Nonalcoholic Steatohepatitis (NASH) by Products
13. Nonalcoholic Steatohepatitis (NASH) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Nonalcoholic Steatohepatitis (NASH) in United States
13.1.2. Percentage Share of drugs marketed for Nonalcoholic Steatohepatitis (NASH) in United States
13.1.3. Market Sales of Nonalcoholic Steatohepatitis (NASH) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Nonalcoholic Steatohepatitis (NASH) in Germany
13.2.1.2. Percentage Share of drugs marketed for Nonalcoholic Steatohepatitis (NASH) in Germany
13.2.1.3. Market Sales of Nonalcoholic Steatohepatitis (NASH) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Nonalcoholic Steatohepatitis (NASH) in France
13.2.2.2. Percentage Share of drugs marketed for Nonalcoholic Steatohepatitis (NASH) in France
13.2.2.3. Market Sales of Nonalcoholic Steatohepatitis (NASH) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Nonalcoholic Steatohepatitis (NASH) in Italy
13.2.3.2. Percentage Share of drugs marketed for Nonalcoholic Steatohepatitis (NASH) in Italy
13.2.3.3. Market Sales of Nonalcoholic Steatohepatitis (NASH) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Nonalcoholic Steatohepatitis (NASH) in Spain
13.2.4.2. Percentage Share of drugs marketed for Nonalcoholic Steatohepatitis (NASH) in Spain
13.2.4.3. Market Sales of Nonalcoholic Steatohepatitis (NASH) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Nonalcoholic Steatohepatitis (NASH) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Nonalcoholic Steatohepatitis (NASH) in United Kingdom
13.2.5.3. Market Sales of Nonalcoholic Steatohepatitis (NASH) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Nonalcoholic Steatohepatitis (NASH) in Japan
13.3.2. Percentage Share of drugs marketed for Nonalcoholic Steatohepatitis (NASH) in Japan
13.3.3. Market Sales of Nonalcoholic Steatohepatitis (NASH) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in 7MM
Table 2: Total Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2028)
Table 6: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2028)
Table 7: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2028)
Table 12: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2028)
Table 15: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2028)
Table 16: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2028)
Table 17: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2028)
Table 22: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2028)
Table 27: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2028)
Table 31: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2028)
Table 32: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2028)
Table 37: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2028)
Table 42:7MM- Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2028)
Table 45: United States-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2028)
Table 48: Germany-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2028)
Table 51: France-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2028)
Table 54: Italy-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2028)
Table 57: Spain-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2028)
Table 60:UK-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2028)
Table 63: Japan-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2028)
Figure 7: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2028)
Figure 12: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2028)
Figure 16: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2028)
Figure 17: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2028)
Figure 22: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2028)
Figure 27: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2028)
Figure 32: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2028)
Figure 37: Treatable Cases of the Nonalcoholic Steatohepatitis (NASH) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2028)
Figure 42:7MM- Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2028)
Figure 45: United States-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2028)
Figure 48: Germany-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2028)
Figure 51: France-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2028)
Figure 54: Italy-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2028)
Figure 57: Spain-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2028)
Figure 60:UK-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Nonalcoholic Steatohepatitis (NASH) in USD MM (2016-2028)
Figure 63: Japan-Market Share Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Nonalcoholic Steatohepatitis (NASH) by Therapies in USD MM (2016-2028)

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$6250
This license allows only one user to access the PDF.

Electronic (PDF)
$12500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$18750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano Dimension

RELATED REPORTS

Global and United States Invisible Dental Braces Market Insights Forecast to 2027
Global and United States Invisible Dental Braces Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-19Z6757
Sun Sep 05 00:00:00 UTC 2021

Add to Cart

Global and China Blincyto Market Insights Forecast to 2027
Global and China Blincyto Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-7U6886
Sun Sep 05 00:00:00 UTC 2021

Add to Cart